An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan.
A Multicenter, Open-label Study to Evaluate the Safety and Tolerability of LCZ696 Treatment in Japanese Heart Failure Patients (NYHA Class II-IV) With Preserved Ejection Fraction After CLCZ696D2301 (PARAGON-HF)
Sponsor: Novartis Pharmaceuticals
Terminated
This study was terminated early because the primary endpoint of PARAGON-HF was not met.
A PHASE3 clinical study on Heart Failure With Preserved Ejection Fraction (HFpEF), this trial is terminated or withdrawn. The trial is conducted by Novartis Pharmaceuticals and has accumulated 7 data snapshots since 2019. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Nov 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Nov 2021 [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
▶ Show 2 earlier versions
-
Oct 2019 — Jan 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
May 2019 — Oct 2019 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Chikushino-shi, Japan , Hachiōji, Japan , Itabashi-ku, Japan , Kanazawa, Japan , Kan’onjichō, Japan , Kashihara, Japan , Kusatsu, Japan , Maebashi, Japan , Morioka, Japan , Sayama, Japan and 6 more locations